Precious Idogun
Royal Oak, MINPI 1386271385
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,757 of the $2,054 with a category attached, or 85.6%. It is spread thinly across 23 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $991, more than ten times the $95 reported in 2023.
Across 47 payments — averaging $43.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$361
- Sanofi$216
- Novartis$203
- Johnson & Johnson$190
- AstraZeneca$162
- GSK$146
- plus $775 from 17 others
What the payments were for
- Food & beverage$1,75786%
- Education$29614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $361 |
| Sanofi | 4 | $216 |
| Novartis | 4 | $203 |
| Johnson & Johnson | 5 | $190 |
| AstraZeneca | 3 | $162 |
| GSK | 2 | $146 |
| Lilly USA, LLC | 2 | $123 |
| Sobi, Inc | 2 | $114 |
| Merck | 4 | $100 |
| Genentech USA, Inc. | 3 | $79 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Caris MPI, Inc. | 1 | $37 |
| Geron Corporation | 1 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $21 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $7,528 |
| Fluconazole | 12 | $722 |
| Allopurinol | 11 | $237 |
| Acyclovir | 14 | $144 |
| Prochlorperazine Maleate | 11 | $124 |
| Levofloxacin | 12 | $81 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.